Characteristics* | Control group (n=170 762) | Patients with autoimmune diseases | |||
---|---|---|---|---|---|
Patients with RA† (n=525) | p Value‡ | Patients with SLE† (n=211) | p Value‡ | ||
Age group | <0.0001 | <0.0001 | |||
<50 years old | 19 924 (11.7) | 29 (5.5) | 73 (34.6) | ||
50–59 years old | 37 297 (21.8) | 77 (14.7) | 51 (24.2) | ||
60–69 years old | 45 798 (26.8) | 179 (34.1) | 57 (27.0) | ||
70–79 years old | 49 026 (28.7) | 195 (37.1) | 28 (13.3) | ||
≥80 years old | 18 717 (11.0) | 45 (8.6) | 2 (0.9) | ||
Age, mean (SD) | 65.3 (12.1) | 68.0 (10.0) | <0.0001 | 55.7 (12.6) | <0.0001 |
Sex§ | <0.0001 | <0.0001 | |||
Female | 47 939 (28.1) | 289 (55.0) | 145 (68.7) | ||
Male | 122 716 (71.9) | 236 (45.0) | 66 (31.3) | ||
Medical comorbidities | |||||
Hypertension | 112 451 (65.9) | 363 (69.1) | 0.11 | 145 (68.7) | 0.38 |
DM | 66 097 (38.7) | 192 (36.6) | 0.32 | 47 (22.3) | <0.0001 |
Hyperlipidaemia | 67 535 (39.6) | 144 (27.4) | <0.0001 | 57 (27.0) | 0.0002 |
CHF | 29 985 (17.6) | 127 (24.2) | <0.0001 | 44 (20.9) | 0.21 |
CKD | 9713 (5.7) | 35 (6.7) | 0.33 | 51 (24.2) | <0.0001 |
ESRD | 7097 (4.2) | 19 (3.6) | 0.54 | 45 (21.3) | <0.0001 |
PAD | 4399 (2.6) | 19 (3.6) | 0.13 | 6 (2.8) | 0.81 |
Prior stroke | 24 578 (14.4) | 78 (14.9) | 0.76 | 37 (17.5) | 0.19 |
COPD | 20 021 (11.7) | 105 (20.0) | <0.0001 | 32 (15.2) | 0.12 |
Dementia | 1749 (1.0) | 5 (1.0) | 0.87 | 0 (0) | 0.29 |
Parkinson's disease | 1540 (0.9) | 5 (1.0) | 0.90 | 2 (1.0) | 0.72 |
ACS | 78 418 (45.9) | 251 (47.8) | 0.39 | 99 (46.9) | 0.77 |
Stenting | 83 087 (48.7) | 311 (59.2) | <0.0001 | 113 (53.6) | 0.15 |
Hospital level | 0.45 | <0.0001 | |||
Medical centre | 70 606 (41.3) | 222 (42.3) | 133 (63.0) | ||
Regional hospital | 81 052 (47.5) | 237 (45.1) | 60 (28.4) | ||
District hospital | 19 104 (11.2) | 66 (12.6) | 18 (8.5) | ||
Total hospital cost (NT$, mean±SD) | 160 421±101 629 | 172 822±105 282 | 0.005 | 177 115±113 617 | 0.02 |
*Data are expressed as patient number (percentage) unless otherwise indicated.
†Ten patients with a combination of RA and SLE were counted in the groups of patients with RA and SLE.
‡The p values were calculated by comparison with the control group.
§Sex data were missing or undetermined in 28 patients (0.01%).
ACS, acute coronary syndrome; CHF, congestive heart failure; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DM, diabetes mellitus; ESRD, end-stage renal disease; NT$, New Taiwan dollar; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.